Literature DB >> 23268707

Different cell cycle modulation by celecoxib at different concentrations.

Young-Mee Kim1, Hongryull Pyo.   

Abstract

Abstract Different cyclooxygenase (COX)-2 inhibitors were known to cause different cell cycle changes. We investigated whether this different effect on cell cycle change was due to concentration-dependent effect. We investigated the effects of celecoxib, a COX-2 selective inhibitor, on cell cycle regulation in irradiated cancer cells that express high or low levels of COX-2. Four stably COX-2 knocked-down or overexpressed cell lines were treated with various concentrations of celecoxib with or without radiation. Celecoxib differentially modulated the cell cycle according to the concentrations applied. G1 arrest was induced at lower concentrations, whereas G2/M arrest was induced at higher concentrations in each cell line tested. Radiation-induced G2/M arrest was enhanced at lower concentrations but reduced at higher concentrations. The cutoff values to divide lower and higher concentrations were cell-type specific. Celecoxib treatment activated Cdc25C and inhibited p21 expression in both unirradiated and irradiated cells, regardless of COX-2 expression. Apoptosis was induced in irradiated cells 48 hours after treatment with celecoxib dependent of COX-2. These results imply that celecoxib deactivates the G2 checkpoint via both Cdc25C- and p21-dependent pathways in irradiated cells, which subsequently die by secondary apoptosis. Cell cycle modulating effects in irradiated cells resulting from treatment with celecoxib may have clinical importance with regard to the potential application of celecoxib in cancer patients undergoing radiotherapy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23268707      PMCID: PMC3589891          DOI: 10.1089/cbr.2012.1264

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  25 in total

Review 1.  Control of mitosis by changes in the subcellular location of cyclin-B1-Cdk1 and Cdc25C.

Authors:  C G Takizawa; D O Morgan
Journal:  Curr Opin Cell Biol       Date:  2000-12       Impact factor: 8.382

Review 2.  Potentiation of DNA-damage-induced cytotoxicity by G2 checkpoint abrogators.

Authors:  A Tenzer; M Pruschy
Journal:  Curr Med Chem Anticancer Agents       Date:  2003-01

Review 3.  Radiation and the cell cycle, revisited.

Authors:  George D Wilson
Journal:  Cancer Metastasis Rev       Date:  2004 Aug-Dec       Impact factor: 9.264

Review 4.  Primary response genes induced by growth factors and tumor promoters.

Authors:  H R Herschman
Journal:  Annu Rev Biochem       Date:  1991       Impact factor: 23.643

5.  In vitro enhancement of tumor cell radiosensitivity by a selective inhibitor of cyclooxygenase-2 enzyme: mechanistic considerations.

Authors:  Uma Raju; Eiko Nakata; Peiying Yang; Robert A Newman; Kian K Ang; Luka Milas
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-11-01       Impact factor: 7.038

6.  Ataxia telangiectasia and Rad3-related overexpressing cancer cells induce prolonged G₂ arrest and develop resistance to ionizing radiation.

Authors:  Young-Mee Kim; Yeo Myoung Lee; Soo-Yeon Park; Hongryull Pyo
Journal:  DNA Cell Biol       Date:  2011-02-07       Impact factor: 3.311

7.  Radiosensitivity enhancement by celecoxib, a cyclooxygenase (COX)-2 selective inhibitor, via COX-2-dependent cell cycle regulation on human cancer cells expressing differential COX-2 levels.

Authors:  You Keun Shin; Ji Sun Park; Hyun Seok Kim; Hyun Jung Jun; Gwi Eon Kim; Chang Ok Suh; Yeon Sook Yun; Hongryull Pyo
Journal:  Cancer Res       Date:  2005-10-15       Impact factor: 12.701

8.  Cyclooxygenase (COX)-2-dependent effects of the inhibitor SC236 when combined with ionizing radiation in mammary tumor cells derived from HER-2/neu mice.

Authors:  Susan Lanza-Jacoby; Adam P Dicker; Sheldon Miller; Francis E Rosato; John T Flynn; Stephanie N Lavorgna; Randy Burd
Journal:  Mol Cancer Ther       Date:  2004-04       Impact factor: 6.261

9.  Suppression of N-methyl-N-nitrosourea/testosterone-induced rat prostate cancer growth by celecoxib: effects on cyclooxygenase-2, cell cycle regulation, and apoptosis mechanism(s).

Authors:  Bhagavathi A Narayanan; Mark S Condon; Maarten C Bosland; Narayanan K Narayanan; Bandaru S Reddy
Journal:  Clin Cancer Res       Date:  2003-08-15       Impact factor: 12.531

10.  A selective cyclooxygenase-2 inhibitor, NS-398, inhibits cell growth by cell cycle arrest in a human malignant fibrous histiocytoma cell line.

Authors:  Hideki Yamashita; Mitsuhiko Osaki; Soichiro Honjo; Haruhiko Yoshida; Ryota Teshima; Hisao Ito
Journal:  Anticancer Res       Date:  2003 Nov-Dec       Impact factor: 2.480

View more
  4 in total

1.  Dephosphorylation of Tak1 at Ser412 greatly contributes to the spermatocyte-specific testis toxicity induced by (5R)-5-hydroxytriptolide in C57BL/6 mice.

Authors:  Xinming Qi; Chunzhu Li; Chunyong Wu; Cunzhi Yu; Mingxia Liu; Man Gao; Chenggang Li; Hong Yan; Jin Ren
Journal:  Toxicol Res (Camb)       Date:  2016-01-07       Impact factor: 3.524

2.  Thromboxane A2 exerts promoting effects on cell proliferation through mediating cyclooxygenase-2 signal in lung adenocarcinoma cells.

Authors:  Run-Yue Huang; Shan-Shan Li; Hui-Zhen Guo; Yu Huang; Xian Zhang; Ming-Yue Li; George Gong Chen; Xing Zeng
Journal:  J Cancer Res Clin Oncol       Date:  2014-01-03       Impact factor: 4.553

3.  Diclofenac down-regulates COX-2 induced expression of CD44 and ICAM-1 in human HT29 colorectal cancer cells.

Authors:  Çağatay Yilmaz; Sadi Köksoy; Tuğçe Çeker; Mutay Aslan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2021-08-26       Impact factor: 3.195

4.  Celecoxib mitigates genotoxicity induced by ionizing radiation in human blood lymphocytes.

Authors:  Seyed Jalal Hosseinimehr; Mahdieh Fathi; Arash Ghasemi; Seyedeh Nesa Rezaeian Shiadeh; Tayyeb Allahverdi Pourfallah
Journal:  Res Pharm Sci       Date:  2017-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.